肝脏移植物抗宿主病与异基因造血干细胞移植后生存不良相关
该研究纳入2003年1月至2010年12月异基因造血干细胞移植(AHSCT)后发生移植后肝功能障碍的249例患者,其中124例发生肝脏GVHD、125例为非肝脏GVHD组,比较两组结局并评估肝活检可行性。竞争风险分析显示,肝脏GVHD独立与更高的非复发死亡及不良的无复发生存和总生存相关;肝活检未见重大并发症,49%的病例证实活检前假设、49%的患者据此调整治疗。
要点
- AHSCT后肝功能障碍患者中,1年急性与慢性肝脏GVHD发生率分别为15.7%和31.0%。
- 100例患者共行112次肝活检,未见重大并发症,49%证实活检前假设、49%据此调整治疗。
核心结论
- 肝脏GVHD与AHSCT后不良生存相关,肝活检在该人群中安全且常有助于指导治疗。
研究设计与样本
- 研究纳入2003年1月至2010年12月AHSCT后发生移植后肝功能障碍的249例患者,其中肝脏GVHD组124例、非肝脏GVHD组125例,比较两组结局并评估肝活检可行性。
主要发现
- 1年急性与慢性肝脏GVHD发生率分别为15.7%和31.0%。
- 含竞争风险事件的时间依存协变量Cox回归分析显示,肝脏GVHD独立与更高的非复发死亡及不良的无复发生存和总生存相关。
- 100例患者共行112次肝活检,未见重大并发症;肝活检在49%的病例中证实活检前假设,并使49%的患者治疗发生调整。
临床怎么用
- 原文指出肝活检在该情况下安全且常有助于指导治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver Graft-versus-host disease (GVHD) is common in patients with post-transplant liver dysfunction following allogeneic hematopoietic stem cell transplantation (AHSCT). Oftentimes, the diagnosis is made clinically, and liver biopsy is deferred. Our objective was to evaluate the risk factors and clinical outcomes of liver GVHD among patients who developed post-transplant liver dysfunction. Additionally, we evaluated the feasibility of liver biopsy in this population. We compared outcomes between liver GVHD and a "non-liver GVHD" group, which consisted of other etiologies of post-transplant liver dysfunction. Between January 2003 and December 2010, 249 patients developed post-transplant liver dysfunction following AHSCT: 124 patients developed liver GVHD and 125 were in the "non-liver GVHD" group. The incidence of acute and chronic liver GVHD at one year was 15.7% and 31.0%, respectively. The competing risk analysis revealed full intensity conditioning regimen (Hazard ratio [HR], 1.76; P = .008) and related donor (HR, 1.68; P = .004) as independent risk factors for liver GVHD. The time-varying covariate Cox regression analysis with competing risk event, demonstrated that liver GVHD was independently associated with higher non-relapse mortality, and adverse relapse-free and overall survival. A total of 112 liver biopsies were performed in 100 patients. No major complications were observed. Liver biopsy confirmed prebiopsy hypotheses in 49% of cases, and led to treatment modification in 49% of patients. Our study shows that liver GVHD is associated with adverse survival. Liver biopsy is safe and often helps directing care in this setting.
引用
- Modi D, Ye JC, Surapaneni M, et al. Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients. Am J Hematol. 2019. PMID: 31292984. doi:10.1002/ajh.25575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。